On the positive side, the presence of biomarkers will enable drug companies to perform smaller, better-targeted clinical studies in order to demonstrate efficacy. In any kind of experiment, a fundamental principle is that the greater the number of subjects or iterations, the greater the confidence in the study’s results.
从积极的角度看，生物指标的出现可以让制药公司进行更小、更有针对性的临床研究，以证明其产品的疗效。不管做什么实验，一条基本原则是试验的对象和次数越多，研究结果就越可信。除非干预能产生深远效果，否则总体而言小型研究会产生具有高度不确定性的结果。